NCT00382109 · OUTCOME

Chimerism

Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission · Source last updated 2019-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Up to 12 months

What was measured

Evaluate the relative contribution of resistance by ALL blasts to the donor immune response as a cause of relapse post transplantation.

Analysis population: We are not able to perform this analysis given the low numbers of blast samples available.

Groups in this outcome

Experiemental

Tacro-MTX/Sirolimus GVHD Prophylaxis

Control

Tacro-MTX GVHD Prophylaxis

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Experiemental	0
Control	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
group Id
OG001
value
0
units
Participants

description

Evaluate the relative contribution of resistance by ALL blasts to the donor immune response as a cause of relapse post transplantation.

groups

description
Tacro-MTX/Sirolimus GVHD Prophylaxis
id
OG000
title
Experiemental
description
Tacro-MTX GVHD Prophylaxis
id
OG001
title
Control

population Description

We are not able to perform this analysis given the low numbers of blast samples available.

reporting Status

POSTED

time Frame

Up to 12 months

title

Chimerism

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice